|

Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening

RECRUITINGN/ASponsored by National Taiwan University Hospital
Actively Recruiting
PhaseN/A
SponsorNational Taiwan University Hospital
Started2025-06-02
Est. completion2027-12-31
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06843499

Summary

This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

* VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
* VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.

Exclusion Criteria:

* The patient does not agree to participate in the trial or is unable to provide informed consent.

Conditions3

Age-Related Macular Degeneration (AMD)DiabetesDiabetic Retinopathy (DR)

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.